Abstract
The fruit fly, Drosophila, is commonly used to study late-onset neurodegenerative diseases due to the combination of powerful genetic tools, cheap and simple husbandry and short lifespan. One widely-used measure of disease progression is the age-dependent decline in motor performance that manifests in most Drosophila neurodegeneration models. This is usually quantified using a simple climbing assay. However, the standard climbing assay lacks sensitivity and suffers from high variability meaning large numbers of flies are needed or bespoke apparatus and software solutions. Here, we present a modification of the open-source, MATLAB-based, DART software to measure the decline in “startle response” with age. We demonstrate that the DART setup is more sensitive to the motor performance decline induced by adult-onset neuronal expression of amyloid beta (Aβ) peptides than a traditional climbing assay despite using smaller cohorts of flies. DART also has the potential to generate multiple metrics of motor behaviour during the startle response. The software requires no coding skills to operate and the required apparatus can be purchased commercially. Therefore, DART is a more useful method than the climbing assay for longitudinal assays of motor performance and will enable higher-throughput screen for genetic and pharmacological modifiers of neurodegeneration. In our proof-of-concept screen for modifiers of Aβ-dependent phenotypes, we identified that in vivo knock-down of p53 in adult neurons is neuroprotective. This supports recent work targeting p53 in vitro and demonstrates the potential for DART to be used to screen for targets that ameliorate neurodegeneration.
Highlights
The short lifespan of Drosophila coupled with powerful tools for genetic manipulation and genome-wide screening combines to make it an attractive model system to study aspects of human neurodegenerative disorders
We demonstrate that the Drosophila ARousal Tracking (DART) setup is more sensitive to the motor performance decline induced by adult-onset neuronal expression of amyloid beta (Ab) peptides than a traditional climbing assay despite using smaller cohorts of flies
A widely-used method to follow the disease course in Drosophila neurodegeneration models is to measure the age-dependent decline in motor function that manifests in almost every case (Bouleau & Tricoire, 2015; Casci & Pandey, 2015; Hewitt & Whitworth, 2017; McGurk et al, 2015)
Summary
The short lifespan of Drosophila coupled with powerful tools for genetic manipulation and genome-wide screening combines to make it an attractive model system to study aspects of human neurodegenerative disorders. Drosophila models have been widely used for types of dementia, including Alzheimer’s disease and frontotemporal dementia, and for various movement disorders, including Parkinson’s disease and amyotrophic lateral sclerosis (reviewed in: Bouleau & Tricoire, 2015; Casci & Pandey, 2015; Hewitt & Whitworth, 2017; McGurk, Berson, & Bonini, 2015). The progressive decline in neural output associated with the disease needs to be measured. The progressive decline in motor function is very commonly used as a measure of neural output. Expression of most of the aggregative proteins associated with human neurodegenerative diseases in the Drosophila CNS, including amyloid beta (Ab) (Beharry, Alaniz, & Alonso, 2013), Tau (Kerr et al, 2011), TDP-43
Published Version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have